Study of IDE892 for advanced solid tumors with MTAP deletion
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must have a specific genetic change called MTAP deletion (this can be tested through a blood or tumor sample).
- Your cancer must be advanced (spread or cannot be removed by surgery) and you must have tried at least one prior treatment.
- You must be able to swallow pills and have regular blood tests and study visits.
- You must be in generally good health (able to do daily activities, with no major heart or liver problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
This early-stage trial tests a new drug called CS08399 in people with advanced or hard-to-treat cancers (solid tumors or lymphoma) that have a specific genetic change called MTAP deletion. The drug may help slow or stop cancer growth in people whose cancers no longer respond to standard treatments.
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Hear when a new NSCLC Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.